This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Drug Development

Biomunex CSO defines lead compounds, early R&D plans

Posted by on 15 July 2017
Share this article

During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks to Scrip about the company's bispecific antibody pipeline and how its candidates are different from other cancer therapies in development in this area. Zhukovsky outlines the company's early development design and the timeline for its lead compounds, which are yet to enter the clinic, in solid and hematological cancers.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Eugene Zhukovsky – CSO, Biomunex

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down